Suven Pharmaceuticals Limited (BOM:543064)
1,225.60
+15.05 (1.24%)
At close: Feb 21, 2025
Suven Pharmaceuticals Statistics
Total Valuation
BOM:543064 has a market cap or net worth of INR 312.21 billion. The enterprise value is 306.55 billion.
Market Cap | 312.21B |
Enterprise Value | 306.55B |
Important Dates
The last earnings date was Wednesday, February 12, 2025.
Earnings Date | Feb 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.37% |
Shares Change (QoQ) | +0.19% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 95.78M |
Valuation Ratios
The trailing PE ratio is 111.81.
PE Ratio | 111.81 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 18.29 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 109.78 |
EV / Sales | 29.24 |
EV / EBITDA | 83.73 |
EV / EBIT | 98.78 |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 0.02 |
Debt / EBITDA | 0.11 |
Debt / FCF | n/a |
Interest Coverage | 34.86 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | 9.50% |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | 8.79M |
Profits Per Employee | 2.34M |
Employee Count | 1,193 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +82.49% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +82.49% |
50-Day Moving Average | 1,109.25 |
200-Day Moving Average | 1,041.53 |
Relative Strength Index (RSI) | 64.05 |
Average Volume (20 Days) | 18,279 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BOM:543064 had revenue of INR 10.48 billion and earned 2.79 billion in profits. Earnings per share was 10.93.
Revenue | 10.48B |
Gross Profit | 6.58B |
Operating Income | 3.10B |
Pretax Income | 3.63B |
Net Income | 2.79B |
EBITDA | 3.66B |
EBIT | 3.10B |
Earnings Per Share (EPS) | 10.93 |
Balance Sheet
The company has 6.56 billion in cash and 394.60 million in debt, giving a net cash position of 6.16 billion.
Cash & Cash Equivalents | 6.56B |
Total Debt | 394.60M |
Net Cash | 6.16B |
Net Cash Per Share | n/a |
Equity (Book Value) | 20.28B |
Book Value Per Share | 77.73 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 62.78%, with operating and profit margins of 29.60% and 26.63%.
Gross Margin | 62.78% |
Operating Margin | 29.60% |
Pretax Margin | 34.64% |
Profit Margin | 26.63% |
EBITDA Margin | 34.92% |
EBIT Margin | 29.60% |
FCF Margin | n/a |
Dividends & Yields
BOM:543064 does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.37% |
Shareholder Yield | -0.37% |
Earnings Yield | 0.89% |
FCF Yield | n/a |
Stock Splits
The last stock split was on September 25, 2020. It was a forward split with a ratio of 2.
Last Split Date | Sep 25, 2020 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |